Showing Results for
- Academic Journals (21)
Search Results
- 21
Academic Journals
- 21
- Search Terms:
- 1From: Leukemia. (Vol. 25, Issue 3) Peer-ReviewedClassical enteropathy-associated T-cell lymphoma (EATL) is an uncommon neoplasm associated with a history of childhood coeliac disease. This tumour is characterized by ulcerating intestinal masses composed of an...
- 2From: Leukemia. (Vol. 25, Issue 3) Peer-ReviewedDespite the success of imatinib mesylate (IM) in the early chronic phase of chronic myeloid leukemia (CML), patients are resistant to IM and other kinase inhibitors in the later stages of CML. Our findings indicate that...
- 3From: Leukemia. (Vol. 25, Issue 3) Peer-ReviewedMultiple genetic hits are detected in patients with acute myeloid leukemia (AML). To investigate this further, we developed a tetracycline-inducible mouse model of AML, in which the initial transforming event,...
- 4From: Leukemia. (Vol. 25, Issue 3) Peer-ReviewedSNS-032 (BMS-387032) is a selective cyclin-dependent kinase (CDK) inhibitor. In this study, we evaluated its effects on primary acute myeloid leukemia (AML) samples (n = 87). In vitro exposure to SNS-032 for 48 h...
- 5From: Leukemia. (Vol. 25, Issue 3) Peer-ReviewedThe deregulation of the homeobox genes as homeoboxB (HOXB)-7 has been previously associated to tumor progression and angiogenesis; here we investigated the potential role of HOXB7 in the pro-angiogenic properties of...
- 6From: Leukemia. (Vol. 25, Issue 3) Peer-ReviewedHistorically, genes targeted by recurrent chromosomal deletions have been identified within the smallest genomic region shared in all patients, the minimally deleted region (MDR). However, deletions this small do not...
- 7From: Leukemia. (Vol. 25, Issue 3) Peer-ReviewedAlthough glucocorticoid (GC) is widely used for treating hematopoietic malignancies including adult T-cell leukemia (ATL), the mechanism by which leukemic cells become resistant to GC in the clinical course remains...
- 8From: Leukemia. (Vol. 25, Issue 3) Peer-ReviewedCD38, a nucleotide-metabolizing ectoenzyme and a receptor, is a negative prognostic marker for chronic lymphocytic leukemia (CLL) patients. CD38 has a genetic polymorphism, with a C [right arrow] G variation in a...
- 9From: Leukemia. (Vol. 25, Issue 3) Peer-ReviewedWe report our experience on rituximab-cyclophosphamide--dexamethasone (RCD) combination therapy for the treatment of autoimmune disorders (AIDs) in 48 chronic lymphocytic leukemia (CLL) patients. Overall, 81% of...
- 10From: Leukemia. (Vol. 25, Issue 3) Peer-ReviewedInfant acute lymphoblastic leukemia (ALL) involving mixed-lineage leukemia (MLL) fusions has attracted a huge interest in basic and clinical research because of its prenatal origin, mixed-lineage phenotype, dismal...
- 11From: Leukemia. (Vol. 25, Issue 3) Peer-ReviewedPrecise regulatory mechanisms are required to appropriately modulate the cellular levels of transcription factors controlling cell fate decisions during blood cell development. In this study, we show that miR-126 is a...
- 12From: Leukemia. (Vol. 25, Issue 3) Peer-ReviewedAbout 40% of patients with myelodysplastic syndromes (MDSs) present with a normal karyotype, and they are facing different courses of disease. To advance the biological understanding and to find molecular prognostic...
- 13From: Leukemia. (Vol. 25, Issue 3) Peer-ReviewedChildhood acute myeloid leukemia (AML) is a heterogeneous disease with an overall poorer outcome as compared with acute lymphoid leukemia. Marked differences in terms of outcome of AML patients have been confirmed to be...
- 14From: Leukemia. (Vol. 25, Issue 3) Peer-ReviewedPatients with secondary acute myeloid leukemia (sAML) are generally thought to have a poor prognosis. As there are no prognostic risk stratification models for patients with sAML available, the aim of this study was to...
- 15From: Leukemia. (Vol. 25, Issue 3) Peer-ReviewedIn spite of the undoubtedly improved outcome in the rituximab era, there is not evidence as yet that immunochemotherapy will eventually cure a significant proportion of patients with follicular lymphoma (FL). Stem cell...
- 16From: Leukemia. (Vol. 25, Issue 3) Peer-ReviewedMLL-rearranged acute lymphoblastic leukemia (ALL) in infants (< 1 year) is the most aggressive type of childhood leukemia. To develop more suitable treatment strategies, a firm understanding of the biology underlying...
- 17From: Leukemia. (Vol. 25, Issue 3) Peer-ReviewedWe report on the outcome of children with advanced primary myelodysplastic syndrome (MDS) transplanted from an HLA-matched sibling (MSD) or an unrelated donor (UD) following a preparative regimen with busulfan,...
- 18From: Leukemia. (Vol. 25, Issue 3) Peer-ReviewedWe describe 70 children with myelodysplastic syndrome (MDS) (refractory cytopenia (n = 31) and refractory anemia with excess blasts (n = 30) or blasts in transformation (n = 9)) who received umbilical cord blood (UCB)...
- 19From: Leukemia. (Vol. 25, Issue 3) Peer-ReviewedRelapse of malignant disease remains the major complication in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after hematopoietic cell transplantation (HCT) with reduced-intensity...
- 20From: Leukemia. (Vol. 25, Issue 3) Peer-ReviewedBlast crisis (BC) is the terminal phase of chronic myeloid leukemia (CML) and is characterized by a rapid expansion of myeloid or lymphoid differentiation-arrested blast cells leading to short median survival. (1,2) In...